BRIEF-U.S. FDA Accepts Gilead’s Application For Investigational Once-Weekly Oral Yeztugo

June 15 (Reuters) – Gilead Sciences, Inc: * U.S. FDA ACCEPTS GILEAD’S APPLICATION FOR INVESTIGATIONAL ONCE-WEEKLY ORAL YEZTUGO, POTENTIALLY THE FIRST LONG-ACTING PILL FOR HIV PREVENTION * GILEAD – FDA

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)